Ozempic and Mounjaro makers point to unexpected anti-aging effects

Blockbuster medications originally designed to manage blood sugar and combat obesity might carry an unexpected secondary benefit: the potential to slow down biological aging. Researchers working with Novo Nordisk and Eli Lilly recently presented intriguing data at the 13th annual Aging Research & Drug Discovery conference, pointing to a measurable reduction in the molecular aging clocks of patients taking these treatments.

Scientists at Novo Nordisk analyzed clinical trial data to understand how semaglutide, the active ingredient in Ozempic and Wegovy, impacts the biomarkers linked to cellular aging. Across multiple measurements, patients using semaglutide exhibited a consistent reduction in aging markers compared to the placebo control groups. Depending on the specific biological clock evaluated, researchers observed an estimated slowdown of two to three years, with heart-related protein markers indicating a reduction of roughly four years.

Simultaneously, a research team at Eli Lilly shared parallel findings regarding tirzepatide, the dual GLP-1 and GIP receptor agonist found in Mounjaro and Zepbound. By examining epigenetic changes in patient DNA that regulate gene activity, the company noted that participants taking the medication appeared to age more slowly than those in the control group.

Despite the promising data, independent experts note several important caveats. The findings remain preliminary and have not yet undergone formal peer review. Furthermore, because the analyses were conducted internally by pharmaceutical scientists rather than third-party researchers, the scientific community is awaiting broader validation. The reliability of molecular aging clocks themselves is still developing, and current studies focus strictly on individuals managing obesity or type 2 diabetes rather than the general population.

Even with these questions remaining, the broader health benefits of GLP-1 medications are already well-documented, particularly in reducing risks for age-related conditions like heart disease. Future clarity may soon emerge, as federal funding now supports clinical trials directly examining whether these drugs can extend longevity and healthy aging in adults over the age of 60.